MyTomorrows raises €10m from EQT, Octopus et al.

Previous investors Sofinnova Partners and Balderton Capital also recommitted capital on this occasion. The latest funding round brings the total raised by the startup to $22.14m.

MyTomorrows will use the funding to invest in new technology and increase its headcount, the group said in a statement. It will also aim to keep adding new countries an clinical trials to its database.

Previous funding
MyTomorrows received a first round of funding in 2012, amounting to $3.8m in total. In February 2014, the startup closed a further $2.2m venture round from various investors; a few months later, Balderton and Sofinnova invested €4.5m in the group through an early-stage venture round, taking a minority stake in the group.

Company
Headquartered in Amsterdam and founded in 2013, MyTomorrows is an online healthcare platform providing access to experimental treatments for people suffering from debilitating diseases. The company currently specialises in medical needs across oncology, central nervous system and orphan diseases. MyTomorrows makes use of programmes known as "compassionate use programmes" to allow patients and physicians to access drugs that are still in development.

The platform has been launched in 17 countries, and its database has indexed 300,000 clinical trials and early access programmes so far, the group claims.

People
Balderton Capital – Mark Evans (general partner).
Sofinnova Partners – Antoine Papiernik (managing partner).
EQT Ventures – Kees Koolen (founding partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Benelux
• Technology
• Benelux
• Netherlands
• Venture
• EQT Ventures
• Sofinnova Partners
• Balderton Capital